Cargando…
Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy
BACKGROUND: Hypofractionation is increasingly being applied in radiotherapy for prostate cancer, requiring higher accuracy of daily treatment deliveries than in conventional image-guided radiotherapy (IGRT). Different adaptive radiotherapy (ART) strategies were evaluated with regard to dosimetric be...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335467/ https://www.ncbi.nlm.nih.gov/pubmed/34348765 http://dx.doi.org/10.1186/s13014-021-01872-9 |
_version_ | 1783733112058937344 |
---|---|
author | Eckl, Miriam Sarria, Gustavo R. Springer, Sandra Willam, Marvin Ruder, Arne M. Steil, Volker Ehmann, Michael Wenz, Frederik Fleckenstein, Jens |
author_facet | Eckl, Miriam Sarria, Gustavo R. Springer, Sandra Willam, Marvin Ruder, Arne M. Steil, Volker Ehmann, Michael Wenz, Frederik Fleckenstein, Jens |
author_sort | Eckl, Miriam |
collection | PubMed |
description | BACKGROUND: Hypofractionation is increasingly being applied in radiotherapy for prostate cancer, requiring higher accuracy of daily treatment deliveries than in conventional image-guided radiotherapy (IGRT). Different adaptive radiotherapy (ART) strategies were evaluated with regard to dosimetric benefits. METHODS: Treatments plans for 32 patients were retrospectively generated and analyzed according to the PACE-C trial treatment scheme (40 Gy in 5 fractions). Using a previously trained cycle-generative adversarial network algorithm, synthetic CT (sCT) were generated out of five daily cone-beam CT. Dose calculation on sCT was performed for four different adaptation approaches: IGRT without adaptation, adaptation via segment aperture morphing (SAM) and segment weight optimization (ART1) or additional shape optimization (ART2) as well as a full re-optimization (ART3). Dose distributions were evaluated regarding dose-volume parameters and a penalty score. RESULTS: Compared to the IGRT approach, the ART1, ART2 and ART3 approaches substantially reduced the V(37Gy)(bladder) and V(36Gy)(rectum) from a mean of 7.4cm(3) and 2.0cm(3) to (5.9cm(3), 6.1cm(3), 5.2cm(3)) as well as to (1.4cm(3), 1.4cm(3), 1.0cm(3)), respectively. Plan adaptation required on average 2.6 min for the ART1 approach and yielded doses to the rectum being insignificantly different from the ART2 approach. Based on an accumulation over the total patient collective, a penalty score revealed dosimetric violations reduced by 79.2%, 75.7% and 93.2% through adaptation. CONCLUSION: Treatment plan adaptation was demonstrated to adequately restore relevant dose criteria on a daily basis. While for SAM adaptation approaches dosimetric benefits were realized through ensuring sufficient target coverage, a full re-optimization mainly improved OAR sparing which helps to guide the decision of when to apply which adaptation strategy. |
format | Online Article Text |
id | pubmed-8335467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83354672021-08-04 Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy Eckl, Miriam Sarria, Gustavo R. Springer, Sandra Willam, Marvin Ruder, Arne M. Steil, Volker Ehmann, Michael Wenz, Frederik Fleckenstein, Jens Radiat Oncol Research BACKGROUND: Hypofractionation is increasingly being applied in radiotherapy for prostate cancer, requiring higher accuracy of daily treatment deliveries than in conventional image-guided radiotherapy (IGRT). Different adaptive radiotherapy (ART) strategies were evaluated with regard to dosimetric benefits. METHODS: Treatments plans for 32 patients were retrospectively generated and analyzed according to the PACE-C trial treatment scheme (40 Gy in 5 fractions). Using a previously trained cycle-generative adversarial network algorithm, synthetic CT (sCT) were generated out of five daily cone-beam CT. Dose calculation on sCT was performed for four different adaptation approaches: IGRT without adaptation, adaptation via segment aperture morphing (SAM) and segment weight optimization (ART1) or additional shape optimization (ART2) as well as a full re-optimization (ART3). Dose distributions were evaluated regarding dose-volume parameters and a penalty score. RESULTS: Compared to the IGRT approach, the ART1, ART2 and ART3 approaches substantially reduced the V(37Gy)(bladder) and V(36Gy)(rectum) from a mean of 7.4cm(3) and 2.0cm(3) to (5.9cm(3), 6.1cm(3), 5.2cm(3)) as well as to (1.4cm(3), 1.4cm(3), 1.0cm(3)), respectively. Plan adaptation required on average 2.6 min for the ART1 approach and yielded doses to the rectum being insignificantly different from the ART2 approach. Based on an accumulation over the total patient collective, a penalty score revealed dosimetric violations reduced by 79.2%, 75.7% and 93.2% through adaptation. CONCLUSION: Treatment plan adaptation was demonstrated to adequately restore relevant dose criteria on a daily basis. While for SAM adaptation approaches dosimetric benefits were realized through ensuring sufficient target coverage, a full re-optimization mainly improved OAR sparing which helps to guide the decision of when to apply which adaptation strategy. BioMed Central 2021-08-04 /pmc/articles/PMC8335467/ /pubmed/34348765 http://dx.doi.org/10.1186/s13014-021-01872-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Eckl, Miriam Sarria, Gustavo R. Springer, Sandra Willam, Marvin Ruder, Arne M. Steil, Volker Ehmann, Michael Wenz, Frederik Fleckenstein, Jens Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy |
title | Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy |
title_full | Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy |
title_fullStr | Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy |
title_full_unstemmed | Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy |
title_short | Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy |
title_sort | dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335467/ https://www.ncbi.nlm.nih.gov/pubmed/34348765 http://dx.doi.org/10.1186/s13014-021-01872-9 |
work_keys_str_mv | AT ecklmiriam dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy AT sarriagustavor dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy AT springersandra dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy AT willammarvin dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy AT ruderarnem dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy AT steilvolker dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy AT ehmannmichael dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy AT wenzfrederik dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy AT fleckensteinjens dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy |